Skip to main content

Publication of transparency notifications

Regulated information Ghent, BELGIUM, May 28, 2026 (GLOBE NEWSWIRE) — Press release Publication of transparency notifications(Article 14(1) of the Law of 2 May 2007 on the disclosure of large shareholders in issuers whose shares are admitted to trading on a regulated market) Biotalys NV (Euronext Brussel : BTLS) (the “Company” or “Biotalys”), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, announces today, in accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings in issuers whose shares are admitted to trading on a regulated market (the ‘Belgian Transparency Act’), that it has received transparency notifications from Agri Investment Fund BV, ASR Vermogensbeheer NV, Gimv NV and Biotech Fonds Vlaanderen NV, and Madeli...

Continue reading

Mortgage Rates Average 6.53%

Primary Mortgage Market Survey®U.S. weekly average mortgage rates as of 05/28/2026MCLEAN, Va., May 28, 2026 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing the 30-year fixed-rate mortgage (FRM) averaged 6.53%. “The 30-year fixed-rate mortgage averaged 6.53% this week,” said Sam Khater, Freddie Mac’s Chief Economist. “Pending home sales have increased three months in a row, indicating there’s latent demand and homebuyers are ready to jump back into the market if mortgage rates decline.” News FactsThe 30-year FRM averaged 6.53% as of May 28, 2026, up from last week when it averaged 6.51%. A year ago at this time, the 30-year FRM averaged 6.89%. The 15-year FRM averaged 5.87%, up from last week when it averaged 5.85%. A year ago at this time,...

Continue reading

QUADIENT SA: Availability and consultation of the information relating to the Ordinary Annual and Extraordinary General Meeting to be held on 18 June 2026

Availability and consultation of the information relating to the Ordinary Annual and Extraordinary General Meeting to be held on 18 June 2026 Paris, 28 May 2026 Quadient SA (the “Company”) informs its shareholders that an ordinary annual and extraordinary General Meeting of the Company will be held physically and broadcast live on Thursday, 18 June 2026 at 2pm (Paris time), at Courtyard par Marriott Paris Arcueil, 6 avenue du Président Allende, 94110 Arcueil. The prior notice of the General Meeting containing the agenda, the draft resolutions presented by the Board of Directors and the description of the participation and voting arrangements for the General Meeting, was published (in French only) in the Bulletin des Annonces Légales Obligatoires n° 56 on 11 May 2026. The Convening Notice, setting out the agenda and containing useful information...

Continue reading

PROACTIS SA – Press Release 28.05.2026 (AFR report publication)

         Press Release Postponement of publication of results and Annual Financial Report for the year ending January 31, 2026 Paris, France – (28 May 2026) – PROACTIS SA (ISIN code: FR0004052561) announces the postponement of the publication, originally scheduled for May 29, 2026, of its results and Annual Financial Report for the year ended January 31, 2026. A significant proportion of Proactis SA’s revenue is with related parties within the wider Proactis Group (defined as PROACTIS TOPCO LIMITED and its subsidiaries). Further, the financing arrangements for the wider Proactis Group (which includes PROACTIS SA and its subsidiaries) are managed by PROACTIS TOPCO LIMITED (the ultimate majority parent company of PROACTIS SA). Therefore, the auditors of PROACTIS SA place reliance on the audit of PROACTIS TOPCO LIMITED. There...

Continue reading

Valneva to Participate at U.S. and European Investor Conferences in June

Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026. Key topics for discussion include Valneva’s commercial stage vaccines and its differentiated portfolio of vaccine candidates, including LB6V (formerly VLA15), the world’s leading Lyme Disease vaccine candidate. LB6V is partnered with Pfizer, who reported topline Phase 3 results demonstrating strong efficacy with no safety concerns. Pfizer is currently planning submissions to regulatory authorities. Institutional investors who would like to meet 1on1 with management at any of the conferences below are asked to submit a request to their representative at the respective...

Continue reading

Renault Group’s climate ambition based on science

Press ReleaseMay 28, 2026  Renault Group’s climate ambition based on science In 2019, Renault Group was the first carmaker to rely on science-based climate targets. Renault Group is announcing the renewal of its science-based targets, with a new approval of its near- and long-term targets by the Science Based Targets initiative. These targets are supported by the product momentum of futuREady strategic plan.Boulogne-Billancourt, May 28, 2026 In 2019, Renault Group was the first carmaker to rely on science-based climate targets. Renault is announcing the renewal of its science-based targets, with a new approval of its near- and long-term targets by the Science Based Targets initiative (SBTi). Current automotive market, energy trend and public policies show a pathway. Along with its plants, products and suppliers, Renault...

Continue reading

Blue Ops Ramps into Full-Rate Production of U.S.-Built Variant 7, Advancing Red Cat’s Autonomy Stack Across Air, Land and Sea

SALT LAKE CITY, May 28, 2026 (GLOBE NEWSWIRE) — Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, today announced that its maritime division, Blue Ops, is ramping into full-rate production of the Variant 7 (V7) uncrewed surface vessel (“USV”), a maritime autonomy platform designed, built and assembled in the United States for U.S. and allied defense missions. The Variant 7 is a mission-adaptable USV powered by a Steyr engine and integrated with a domestic autonomy, command-and-control, communications, and mission systems stack. As the U.S. -developed platform advanced from early prototype to production, Blue Ops prioritized U.S.-made and NDAA-compliant components across its navigation, control, marine hardware...

Continue reading

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors PERFORMA Phase 3 trial to further evaluate the broad metabolic and liver-related effects of pemvidutide GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced elevated lipids while improving multiple cardiometabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis (MASH). The findings demonstrated reductions in triglycerides...

Continue reading

VPG to Participate in Investor Conferences in June 2026

Company to Participate in Noble Growth Conference and East Coast IDEAS Conference CHESTERBROOK, Pa., May 28, 2026 (GLOBE NEWSWIRE) — Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, announced today that it will present at the following investor conferences in June 2026:Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference.June 3 & 4, 2026.A webcast of VPG’s presentation, which is scheduled for June 3, 2026 at 11:30AM ET, can be accessed via the following link: VPG webinar at Noble Conference or on VPG’s website at ir.vpgsensors.com/events. Qualified investors can schedule a virtual 1×1 with VPG management by contacting gpigato@noblecapitalmarkets.com.16th East Coast IDEAS Conference.June 10, 2026, in New York, NY.A webcast of VPG’s presentation...

Continue reading

GulfStar Group Announces the Acquisition of Cal-Chlor by PVS Chemicals

HOUSTON, May 28, 2026 (GLOBE NEWSWIRE) — GulfStar Group (“GulfStar”) is pleased to announce the acquisition of Cal-Chlor Corp. (“Cal-Chlor” or the “Company”) by PVS Chemicals, Inc. (“PVS Chemicals”). GulfStar served as the exclusive financial advisor to Cal-Chlor throughout the transaction, which closed on April 30, 2026. Founded in 1982 and headquartered in Lafayette, Louisiana, Cal-Chlor is the largest independent provider of value-added packaging and distribution solutions to the North American calcium chloride marketplace. Cal-Chlor’s custom services include product manufacturing and packaging capabilities across a broad range of form factors and modalities, regulatory-compliant labeling solutions for a variety of end-use markets and comprehensive logistics planning for worldwide delivery. Through a long-term and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.